Inlet Private Wealth LLC Increases Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX)

Inlet Private Wealth LLC boosted its stake in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 25.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 236,740 shares of the biopharmaceutical company's stock after purchasing an additional 48,280 shares during the period. Royalty Pharma makes up approximately 1.6% of Inlet Private Wealth LLC's holdings, making the stock its 17th largest position. Inlet Private Wealth LLC's holdings in Royalty Pharma were worth $6,039,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Blue Trust Inc. grew its position in shares of Royalty Pharma by 31.3% during the fourth quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company's stock worth $45,000 after purchasing an additional 376 shares in the last quarter. Aurora Investment Counsel lifted its stake in shares of Royalty Pharma by 1.0% in the 3rd quarter. Aurora Investment Counsel now owns 50,441 shares of the biopharmaceutical company's stock valued at $1,427,000 after purchasing an additional 512 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Royalty Pharma by 31.4% during the 4th quarter. GAMMA Investing LLC now owns 2,471 shares of the biopharmaceutical company's stock worth $63,000 after acquiring an additional 590 shares during the last quarter. Values First Advisors Inc. raised its position in Royalty Pharma by 7.6% during the 3rd quarter. Values First Advisors Inc. now owns 10,412 shares of the biopharmaceutical company's stock valued at $295,000 after purchasing an additional 738 shares in the last quarter. Finally, M&T Bank Corp raised its position in shares of Royalty Pharma by 4.3% in the 3rd quarter. M&T Bank Corp now owns 18,749 shares of the biopharmaceutical company's stock worth $531,000 after acquiring an additional 779 shares in the last quarter. Hedge funds and other institutional investors own 54.35% of the company's stock.

Royalty Pharma Stock Up 0.6 %

Shares of RPRX stock traded up $0.19 during trading hours on Wednesday, reaching $31.45. 2,253,559 shares of the stock were exchanged, compared to its average volume of 4,134,476. The business's fifty day moving average is $27.53 and its two-hundred day moving average is $27.57. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.54 and a quick ratio of 1.54. The firm has a market capitalization of $18.53 billion, a P/E ratio of 16.30 and a beta of 0.49. Royalty Pharma plc has a 12-month low of $24.05 and a 12-month high of $32.21.

Royalty Pharma Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 21st will be issued a $0.22 dividend. This is an increase from Royalty Pharma's previous quarterly dividend of $0.21. This represents a $0.88 annualized dividend and a dividend yield of 2.80%. The ex-dividend date is Friday, February 21st. Royalty Pharma's dividend payout ratio is presently 43.52%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on RPRX shares. Citigroup cut their price objective on Royalty Pharma from $60.00 to $40.00 and set a "buy" rating on the stock in a report on Friday, October 25th. TD Cowen raised shares of Royalty Pharma to a "strong-buy" rating in a research note on Tuesday, December 24th. Finally, StockNews.com raised shares of Royalty Pharma from a "hold" rating to a "buy" rating in a research report on Tuesday, November 5th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Royalty Pharma has an average rating of "Buy" and a consensus target price of $41.67.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.